These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 21054535

  • 1. Re: Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Kittleson MD, Bonagura JD.
    J Vet Intern Med; 2010; 24(6):1245-6; author reply 1247-8. PubMed ID: 21054535
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
    Bernay F, Bland JM, Häggström J, Baduel L, Combes B, Lopez A, Kaltsatos V.
    J Vet Intern Med; 2010; 24(2):331-41. PubMed ID: 20102506
    [Abstract] [Full Text] [Related]

  • 3. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
    Thomason JD, Rockwell JE, Fallaw TK, Calvert CA.
    J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic management of myxomatous mitral valve disease in dogs.
    Atkins CE, Häggström J.
    J Vet Cardiol; 2012 Mar; 14(1):165-84. PubMed ID: 22386553
    [Abstract] [Full Text] [Related]

  • 5. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease.
    Häggström J, Höglund K, Borgarelli M.
    J Small Anim Pract; 2009 Sep; 50 Suppl 1():25-33. PubMed ID: 19765217
    [Abstract] [Full Text] [Related]

  • 6. Geriatric heart diseases in dogs.
    Hamlin RL.
    Vet Clin North Am Small Anim Pract; 2005 May; 35(3):597-615. PubMed ID: 15833561
    [Abstract] [Full Text] [Related]

  • 7. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.
    Lefebvre HP, Ollivier E, Atkins CE, Combes B, Concordet D, Kaltsatos V, Baduel L.
    J Vet Intern Med; 2013 May; 27(5):1083-91. PubMed ID: 23869534
    [Abstract] [Full Text] [Related]

  • 8. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS, Häggström J, Pedersen HD, Hansson K, Järvinen AK, Haukka J, Kvart C.
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [Abstract] [Full Text] [Related]

  • 9. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J, Boswood A, O'Grady M, Jöns O, Smith S, Swift S, Borgarelli M, Gavaghan B, Kresken JG, Patteson M, Ablad B, Bussadori CM, Glaus T, Kovacević A, Rapp M, Santilli RA, Tidholm A, Eriksson A, Belanger MC, Deinert M, Little CJ, Kvart C, French A, Rønn-Landbo M, Wess G, Eggertsdottir AV, O'Sullivan ML, Schneider M, Lombard CW, Dukes-McEwan J, Willis R, Louvet A, DiFruscia R.
    J Vet Intern Med; 2008 Sep; 22(5):1124-35. PubMed ID: 18638016
    [Abstract] [Full Text] [Related]

  • 10. Use of human spironolactone in dogs with heart failure.
    Broadfoot F, McGuire P.
    Vet Rec; 2008 Apr 05; 162(14):460. PubMed ID: 18390864
    [No Abstract] [Full Text] [Related]

  • 11. Hydralazine Therapy for severe mitral regurgitation in a dog.
    Kittleson MD, Hamlin RL.
    J Am Vet Med Assoc; 1981 Nov 01; 179(9):903-5. PubMed ID: 7341606
    [No Abstract] [Full Text] [Related]

  • 12. Use of human spironolactone in dogs with heart failure.
    Watson P.
    Vet Rec; 2008 May 03; 162(18):599. PubMed ID: 18453386
    [No Abstract] [Full Text] [Related]

  • 13. Use of human spironolactone in dogs with heart failure.
    Whitehead M.
    Vet Rec; 2008 May 03; 162(18):599. PubMed ID: 18453385
    [No Abstract] [Full Text] [Related]

  • 14. Oral hydralazine therapy for chronic mitral regurgitation in the dog.
    Kittleson MD, Eyster GE, Olivier NB, Anderson LK.
    J Am Vet Med Assoc; 1983 Jun 01; 182(11):1205-9. PubMed ID: 6863134
    [No Abstract] [Full Text] [Related]

  • 15. Pathology of myxomatous mitral valve disease in the dog.
    Fox PR.
    J Vet Cardiol; 2012 Mar 01; 14(1):103-26. PubMed ID: 22386587
    [Abstract] [Full Text] [Related]

  • 16. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.
    Kittleson M, Rishniw M, Pion P.
    J Vet Intern Med; 2009 Mar 01; 23(3):445-6; author reply 447-8. PubMed ID: 19645830
    [No Abstract] [Full Text] [Related]

  • 17. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: A retrospective study of 141 cases.
    Kittleson M, Rishniw M, Pion P, Kass P.
    J Vet Intern Med; 2009 Mar 01; 23(5):953-4; author reply 955-6. PubMed ID: 19737176
    [No Abstract] [Full Text] [Related]

  • 18. Chordae tendineae rupture in dogs with degenerative mitral valve disease: prevalence, survival, and prognostic factors (114 cases, 2001-2006).
    Serres F, Chetboul V, Tissier R, Sampedrano CC, Gouni V, Nicolle AP, Pouchelon JL.
    J Vet Intern Med; 2007 Mar 01; 21(2):258-64. PubMed ID: 17427386
    [Abstract] [Full Text] [Related]

  • 19. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease.
    Sargent J, Muzzi R, Mukherjee R, Somarathne S, Schranz K, Stephenson H, Connolly D, Brodbelt D, Fuentes VL.
    J Vet Cardiol; 2015 Mar 01; 17(1):1-12. PubMed ID: 25586168
    [Abstract] [Full Text] [Related]

  • 20. Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration.
    Kijtawornrat A, Komolvanich S, Saengklub N, Pirintr P, Boonpala P, Buranakarl C.
    J Vet Med Sci; 2017 Apr 20; 79(4):788-794. PubMed ID: 28302926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.